Surgical strategy for bile duct cancer: Advances and current limitations. - Wikidata - awgldk - TriplyDB

Surgical strategy for bile duct cancer: Advances and current limitations.

Surgical strategy for bile duct cancer: Advances and current limitations.

http://www.wikidata.org/entity/Q34629377

about

The significance of genetics for cholangiocarcinoma development Adjuvant therapy in biliary tract and gall bladder carcinomas: a review.Volume change and liver parenchymal signal intensity in Gd-EOB-DTPA-enhanced magnetic resonance imaging after portal vein embolization prior to hepatectomy.Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma Prognostic factors following surgical resection of distal bile duct cancer.Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma.Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection.Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer.Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up.Upregulated expression of Mina53 in cholangiocarcinoma and its clinical significance.Principles of surgical resection in hilar cholangiocarcinoma.Liver transplantation for hilar cholangiocarcinoma--a single-centre experience.Surgical management trends for cholangiocarcinoma in the USA 1998-2009.Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.Cholangiocarcinoma--current classification and challenges towards personalised medicine.Intraoperative placement of external biliary drains for prevention and treatment of bile leaks after extended liver resection without bilioenteric anastomosis.Utility of intraoperative cytology of resection margins in biliary tract and pancreas tumors.ERCC1 mRNA expression as a postoperative prognostic marker in extrahepatic bile duct cancer.Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives

P2860

Q26865749-69C44C94-18A9-4A3C-BB2E-0CD073232761 Q33593250-96BB7AEE-B092-49D9-A044-26E6D08200C4 Q34270959-B07BD485-2FD5-4DBB-996E-B1A777E730AA Q36520529-1B388113-C9B7-4DE2-AA15-EABC40C86ACC Q36848730-0375EB20-70DB-45D6-A7AE-EE0417B079D9 Q37325283-ECE45EFA-7C14-40DB-8A6E-6B9C114E7693 Q37619847-9C32DF49-EDE7-4E32-A936-B8198418F0EB Q38127390-15457C16-C74A-4B88-8D1E-0AEC099D0CE6 Q40399436-A8A4065E-21BA-4C06-8148-01C5A375548C Q40776257-1428444A-920A-46FA-A37D-074364B67AFB Q42225304-1107C53F-AD3F-4C8F-9998-D70367105791 Q43063932-F960FF9E-7C5D-4F5D-9B52-E8FE8FD08E8D Q44785186-C5A5B08A-807E-4FE3-BA65-F4F7F0117BD8 Q46034252-6F54329F-5FDA-4559-965D-1DCEB515F2CC Q47640222-E0AF98A6-5F81-47AD-A2C7-7E1EB6036FFA Q51548085-0C58FB5B-0FA6-4935-AB16-A8B855451B5C Q52883023-B1A30CDE-D464-4CA0-9107-6849ECFAECF8 Q53676254-DE8DD5BA-E73A-49C2-A7B7-230F41B94F26 Q54211675-52D813FF-26E7-4769-89A6-6B147DABDF37 Q57139983-D6034585-A867-44CA-BE1C-C97795B06887

P2860

Surgical strategy for bile duct cancer: Advances and current limitations.

http://www.wikidata.org/entity/Q34629377

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Surgical strategy for bile duct cancer: Advances and current limitations.

@ast

Surgical strategy for bile duct cancer: Advances and current limitations.

@en

Surgical strategy for bile duct cancer: Advances and current limitations.

@nl

type

label

Surgical strategy for bile duct cancer: Advances and current limitations.

@ast

Surgical strategy for bile duct cancer: Advances and current limitations.

@en

Surgical strategy for bile duct cancer: Advances and current limitations.

@nl

prefLabel

Surgical strategy for bile duct cancer: Advances and current limitations.

@ast

Surgical strategy for bile duct cancer: Advances and current limitations.

@en

Surgical strategy for bile duct cancer: Advances and current limitations.

@nl

P1433

Q34629377-A7451CF0-A450-4296-8F37-344ACCAD9E9A

P1476

Q34629377-18FC1509-4A79-4516-863A-144E35B02ABF

P2093

Q34629377-956F2C45-4899-4B06-8A19-01B9856ED3AF

Q34629377-BC073019-9C8F-4799-A1D6-DBAAA0A880FC

Q34629377-E27AA13C-313F-49C5-97A4-87A3CDBEADDC

P2860

Q34629377-01C0F53F-5765-4242-B585-374E8163CA75

Q34629377-0282CF9A-99FE-440E-AB1D-4BEA8CD0B778

Q34629377-02EEECAC-83C6-472F-91D8-72F2E65C30D2

Q34629377-02F3879B-1347-4AAD-A418-C4FCA8222AB2

Q34629377-03F8049A-B37F-4A2D-85FF-054410E5FE76

Q34629377-05C9FBBF-E5DA-4B10-8F8C-A57C7B4F2039

Q34629377-09E030EB-56AB-43D8-BC22-DC288A2B224B

Q34629377-0A573BAD-B521-4277-A74A-0E32E2B0857A

Q34629377-0CF5EF61-7455-47A1-8623-0A1A6951831C

Q34629377-0DC0F7CD-9088-4409-8A0B-FE7B321F7B71

P304

Q34629377-0AC9B011-31FC-4347-980E-B3CFB80EAB00

P31

Q34629377-DCCDBD3B-4468-4E7E-8FB4-25C1681092EB

P356

Q34629377-4B17256E-1B3C-478B-843E-4F86BDD0D4F3

P433

Q34629377-DEE6C88C-AB7E-4019-B174-675FD7F48D1E

P478

Q34629377-195DE46C-429F-4399-8685-EECE23E1A6BB

P577

Q34629377-54031FA0-D398-4821-B9AD-A14D72DAEC44

P5875

Q34629377-BB747786-7489-4F0E-838C-353A0F4990FA

P698

Q34629377-CD4072CC-E9F5-47E8-8255-47C443627EAF

P932

Q34629377-8BCC8D5E-F50D-4051-A125-EA8603A136A6

P356

P1433

World journal of clinical oncology

P1476

Surgical strategy for bile duct cancer: Advances and current limitations.

@en

P2093

Daijo Hashimoto

http://www.w3.org/2001/XMLSchema#string

Nobuhisa Akamatsu

http://www.w3.org/2001/XMLSchema#string

Yasuhiko Sugawara

http://www.w3.org/2001/XMLSchema#string

P2860

Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival

Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma

Actual long-term outcome of extrahepatic bile duct cancer after surgical resection

A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma

Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage.

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.

Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma.

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.

P304

94-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5306/WJCO.V2.I2.94

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51156898

http://www.w3.org/2001/XMLSchema#string

P698

21603318

http://www.w3.org/2001/XMLSchema#string

P932

3095469

http://www.w3.org/2001/XMLSchema#string